BioCentury | Apr 8, 2021
Deals

Rounding up intranasal COVID-19 vaccines: Data Byte

...an intramuscular (IM) route of administration, has a Phase I intranasal trial listed by the University of Oxford...
...routes of administration. Discontinued programs are not shown. Data are as of Apr. 7. Winnie Pong AstraZeneca plc University of Oxford Vaccitech...
BioCentury | Apr 7, 2021
Product Development

Latest cut of data shows AZ vaccine has higher rates of rare thrombosis

...Economic Area who received Vaxzevria (AZD1222) from University of Oxford...
BioCentury | Apr 1, 2021
Product Development

COVID roundup: BioNTech-Pfizer vaccine protects adolescents; plus AZ, GSK-Novavax and Amazon

...regulators had limited use of the adenoviral vector vaccine from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and the University of Oxford...
BioCentury | Mar 18, 2021
Product Development

EMA says AstraZeneca COVID-19 vaccine safe, calls for continued vigilance

...of vaccination. AstraZeneca plc (LSE:AZN; NASDAQ:AZN), which developed the COVID-19 Vaccine AstraZeneca together with the University of Oxford...
...vigilance and reporting are intended to address that need, she added. Steve Usdin European Medicines Agency (EMA) AstraZeneca plc University of Oxford covid-19 cov19count cov19pol cov19count cov19pol...
BioCentury | Mar 17, 2021
Finance

Vaccitech’s $168M round to fund clinical work on three vaccines using heterologous prime-boost platform

...Inc. (NASDAQ:GILD), Monaco Constitutional Reserve Fund, and Future Planet Capital also participated.Spun out of the University of Oxford...
...vaccine from AstraZeneca plc (LSE:AZN; NYSE:AZN), which uses only the ChAdOx1 vector. Vaccitech and the University of Oxford...
BioCentury | Mar 15, 2021
Product Development

Citing ‘clear scientific evidence,’ AZ seeks to reassure jittery Europe on vaccine’s safety

...and Spain in pausing vaccinations with the vaccine, which was developed in tandem with the University of Oxford.EMA’s...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...by Oxford Sciences Innovation (OSI) with participation from fellow Orbit investors RT Ventures, Borealis Ventures, University of Oxford...
...out of Oxford to develop neoantigen T cell therapiesSingula Bio Ltd., which spun out of University of Oxford...
BioCentury | Feb 25, 2021
Product Development

J&J’s COVID vaccine cuts asymptomatic infection: Data Byte

...number of subjects as the treatment groups. Sandi Wong Ad26.COV2.S (JNJ-78436735) COVID-19 Vaccine (AZD1222, ChAdOx1 nCoV-19) Johnson & Johnson AstraZeneca plc University of Oxford covid19 covid-19 cov19count cov19sci bee2021 cov19count cov19sci...
BioCentury | Feb 24, 2021
Product Development

U.K. RECOVERY trial’s expansion to Asia, Africa sites offers access to broader scope of patients, ‘safety net’

...it may be an additional benefit in countries with a different dominant strain of SARS-CoV-2.The University of Oxford-led...
...dexamethasone, said Horby, who is a professor of emerging infectious diseases and global health in the University of Oxford’s...
...the pandemic, most have yet to produce actionable data due to the fragmented clinical trial ecosystem. Danielle Golovin University of Oxford bee2021 cov19count covid-19 cov19count...
BioCentury | Feb 23, 2021
Product Development

U.K. adds to real-world data backing flexible COVID vaccine schedule

...the first and second doses Comirnaty. The recommendation also applies to COVID-19 Vaccine AstraZeneca from the University of Oxford...
Items per page:
1 - 10 of 629
BioCentury | Apr 8, 2021
Deals

Rounding up intranasal COVID-19 vaccines: Data Byte

...an intramuscular (IM) route of administration, has a Phase I intranasal trial listed by the University of Oxford...
...routes of administration. Discontinued programs are not shown. Data are as of Apr. 7. Winnie Pong AstraZeneca plc University of Oxford Vaccitech...
BioCentury | Apr 7, 2021
Product Development

Latest cut of data shows AZ vaccine has higher rates of rare thrombosis

...Economic Area who received Vaxzevria (AZD1222) from University of Oxford...
BioCentury | Apr 1, 2021
Product Development

COVID roundup: BioNTech-Pfizer vaccine protects adolescents; plus AZ, GSK-Novavax and Amazon

...regulators had limited use of the adenoviral vector vaccine from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and the University of Oxford...
BioCentury | Mar 18, 2021
Product Development

EMA says AstraZeneca COVID-19 vaccine safe, calls for continued vigilance

...of vaccination. AstraZeneca plc (LSE:AZN; NASDAQ:AZN), which developed the COVID-19 Vaccine AstraZeneca together with the University of Oxford...
...vigilance and reporting are intended to address that need, she added. Steve Usdin European Medicines Agency (EMA) AstraZeneca plc University of Oxford covid-19 cov19count cov19pol cov19count cov19pol...
BioCentury | Mar 17, 2021
Finance

Vaccitech’s $168M round to fund clinical work on three vaccines using heterologous prime-boost platform

...Inc. (NASDAQ:GILD), Monaco Constitutional Reserve Fund, and Future Planet Capital also participated.Spun out of the University of Oxford...
...vaccine from AstraZeneca plc (LSE:AZN; NYSE:AZN), which uses only the ChAdOx1 vector. Vaccitech and the University of Oxford...
BioCentury | Mar 15, 2021
Product Development

Citing ‘clear scientific evidence,’ AZ seeks to reassure jittery Europe on vaccine’s safety

...and Spain in pausing vaccinations with the vaccine, which was developed in tandem with the University of Oxford.EMA’s...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...by Oxford Sciences Innovation (OSI) with participation from fellow Orbit investors RT Ventures, Borealis Ventures, University of Oxford...
...out of Oxford to develop neoantigen T cell therapiesSingula Bio Ltd., which spun out of University of Oxford...
BioCentury | Feb 25, 2021
Product Development

J&J’s COVID vaccine cuts asymptomatic infection: Data Byte

...number of subjects as the treatment groups. Sandi Wong Ad26.COV2.S (JNJ-78436735) COVID-19 Vaccine (AZD1222, ChAdOx1 nCoV-19) Johnson & Johnson AstraZeneca plc University of Oxford covid19 covid-19 cov19count cov19sci bee2021 cov19count cov19sci...
BioCentury | Feb 24, 2021
Product Development

U.K. RECOVERY trial’s expansion to Asia, Africa sites offers access to broader scope of patients, ‘safety net’

...it may be an additional benefit in countries with a different dominant strain of SARS-CoV-2.The University of Oxford-led...
...dexamethasone, said Horby, who is a professor of emerging infectious diseases and global health in the University of Oxford’s...
...the pandemic, most have yet to produce actionable data due to the fragmented clinical trial ecosystem. Danielle Golovin University of Oxford bee2021 cov19count covid-19 cov19count...
BioCentury | Feb 23, 2021
Product Development

U.K. adds to real-world data backing flexible COVID vaccine schedule

...the first and second doses Comirnaty. The recommendation also applies to COVID-19 Vaccine AstraZeneca from the University of Oxford...
Items per page:
1 - 10 of 629